Across TCGA pan-cancer cohorts, NDUFA12 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NDUFA12 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher NDUFA12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NDUFA12 expression acts as an unfavorable survival marker.

PRAD and BLCA are the cancer types where NDUFA12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.099	0.886	<.001	6	view →
BLCA	DFS	Median	III,IV	0.100	0.572	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NDUFA12 tumor-vs-normal RNA expression · all NDUFA12 data types